In his research, Andrew J. Lotery undertakes multidisciplinary study on Ophthalmology and Visual acuity. While working on this project, he studies both Visual acuity and Macular degeneration. While working on this project, Andrew J. Lotery studies both Macular degeneration and Bevacizumab. In his works, he conducts interdisciplinary research on Bevacizumab and Ranibizumab. His Chemotherapy research extends to Ranibizumab, which is thematically connected. In his papers, Andrew J. Lotery integrates diverse fields, such as Chemotherapy and Oncology. Andrew J. Lotery merges many fields, such as Oncology and Ophthalmology, in his writings. His Vascular endothelial growth factor study frequently links to related topics such as VEGF receptors. Andrew J. Lotery frequently studies issues relating to Vascular endothelial growth factor and VEGF receptors.
His Mutation study focuses on Missense mutation and Gene mutation. He integrates Missense mutation and Mutation in his research. He is investigating Bevacizumab as part of his Ranibizumab and Aflibercept and Bevacizumab study. Andrew J. Lotery integrates many fields, such as Cohort study, Prospective cohort study and Cohort, in his works. His Prospective cohort study study typically links adjacent topics like Surgery. His Surgery study frequently links to adjacent areas such as Refractive error. He connects Cohort with Cohort study in his research. He performs integrative Ophthalmology and Neuro-ophthalmology research in his work. He merges Neuro-ophthalmology with Glaucoma in his study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
Heribert Schunkert;Inke R. König;Sekar Kathiresan;Muredach P. Reilly.
Nature Genetics (2011)
A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants
Lars G. Fritsche;Wilmar Igl;Jessica N.Cooke Bailey;Felix Grassmann.
Nature Genetics (2016)
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
Usha Chakravarthy;Simon P. Harding;Chris A. Rogers;Susan M. Downes.
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial
Robert E MacLaren;Robert E MacLaren;Markus Groppe;Markus Groppe;Alun R Barnard;Charles L Cottriall.
The Lancet (2014)
Seven new loci associated with age-related macular degeneration
Lars G. Fritsche;Lars G. Fritsche;Wei Chen;Wei Chen;Matthew Schu;Brian L. Yaspan.
Nature Genetics (2013)
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Usha Chakravarthy;Simon P Harding;Chris A Rogers;Susan M Downes.
The Lancet (2013)
A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy.
Edwin M. Stone;Andrew J. Lotery;Francis L. Munier;Elise Héon.
Nature Genetics (1999)
Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma
Gudmar Thorleifsson;G Bragi Walters;Alex W Hewitt;Alex W Hewitt;Gisli Masson.
Nature Genetics (2010)
Missense variations in the fibulin 5 gene and age-related macular degeneration.
Edwin M. Stone;Terry A. Braun;Stephen R. Russell;Markus H. Kuehn.
The New England Journal of Medicine (2004)
Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future
Johanna M. Colijn;Gabriëlle H.S. Buitendijk;Elena Prokofyeva;Dalila Alves.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: